Key Takeaways BSX's MedSurg growth is fueled by endoscopy, neuromodulation, and global urology market share gains. BSX's WATCHMAN sales rose 24% in Q1 2025, driven by new DRG rules and next-gen device adoption. Recent acquisitions added 400bps to Q1 sales and drove 18.2% organic revenue growth for BSX.Boston Scientific’s (BSX) robust MedSurg segment, driven by endoscopy, neuromodulation and urology businesses, is poised for further growth in the upcoming quarters. The long-term prospects of the WATCHMAN d ...